Homeopathy for Covid-19 in primary care

Homeopathy for Covid-19 in primary care: randomized, parallel-group, double-blind, placebo-controlled, clinical trial - Homeopathy for Covid-19 in primary care: randomized, parallel-group, double-blind, placebo-controlled, clinical trial (Covid-Simile study)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040602

Enrollment

100

Registered

2020-06-01

Start date

2020-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cases of Covid-19

Interventions

One drop of a (30% hydroalcoholic) solution of Natrum muriaticum LM2 taken orally every 4 hours (6 doses/day) while there is fever, cough, tiredness or pain (headache, sore throat, muscle aches, chest

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Flu-like syndrome and a positive RT-PCR for SARS-CoV-2. Willingness to give informed consent and to comply with the study procedures will also be required.

Exclusion criteria

Exclusion criteria: Severe acute respiratory syndrome

Design outcomes

Primary

Measure	Time frame
time to recovery, defined as the number of days elapsed before all the most common Covid-19 flu-like symptoms are recorded as mild or absent.	—

Secondary

Measure	Time frame
recovery time for each of the Covid-19 symptoms; score of the scale created for the study (Covid-Simile scale); medicines used during the 14 days of study participation; number of visits to emergency services; number of hospitalizations; other symptoms and Adverse Events.	—

Countries

South America

Contacts

Public ContactUbiratan Adler

Sao Carlos Federal University Medicine Department

ubiratanadler@ufscar.br00551633519420

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026